1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Vaccine Adjuvants Industry Impact
5.2. COVID-19 Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Vaccine Adjuvants Market Revenue and Volume, by Type
8.1.1 Pathogen
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Adjuvant EMULSION
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Particulate
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Combination
8.1.4.1. Market Revenue and Volume Forecast
8.1.5. Others
8.1.5.1. Market Revenue and Volume Forecast
9.1. Vaccine Adjuvants Market Revenue and Volume, by Application
9.1.1. Infectious DISEASE
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Cancer
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Others
9.1.3.1. Market Revenue and Volume Forecast
10.1. Vaccine Adjuvants Market Revenue and Volume, by Administrator
10.1.1. Oral
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Intradermal
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Intranasal
10.1.3.1. Market Revenue and Volume Forecast
10.1.4. Intramuscular
10.1.4.1. Market Revenue and Volume Forecast
10.1.5. Others
10.1.5.1. Market Revenue and Volume Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Type
11.1.2. Market Revenue and Volume Forecast, by Application
11.1.3. Market Revenue and Volume Forecast, by Administrator
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Type
11.1.4.2. Market Revenue and Volume Forecast, by Application
11.1.4.3. Market Revenue and Volume Forecast, by Administrator
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Type
11.1.5.2. Market Revenue and Volume Forecast, by Application
11.1.5.3. Market Revenue and Volume Forecast, by Administrator
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Type
11.2.2. Market Revenue and Volume Forecast, by Application
11.2.3. Market Revenue and Volume Forecast, by Administrator
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Type
11.2.4.2. Market Revenue and Volume Forecast, by Application
11.2.4.3. Market Revenue and Volume Forecast, by Administrator
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Type
11.2.5.2. Market Revenue and Volume Forecast, by Application
11.2.5.3. Market Revenue and Volume Forecast, by Administrator
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Type
11.2.6.2. Market Revenue and Volume Forecast, by Application
11.2.6.3. Market Revenue and Volume Forecast, by Administrator
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Type
11.2.7.2. Market Revenue and Volume Forecast, by Application
11.2.7.3. Market Revenue and Volume Forecast, by Administrator
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Type
11.3.2. Market Revenue and Volume Forecast, by Application
11.3.3. Market Revenue and Volume Forecast, by Administrator
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Type
11.3.4.2. Market Revenue and Volume Forecast, by Application
11.3.4.3. Market Revenue and Volume Forecast, by Administrator
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Type
11.3.5.2. Market Revenue and Volume Forecast, by Application
11.3.5.3. Market Revenue and Volume Forecast, by Administrator
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Type
11.3.6.2. Market Revenue and Volume Forecast, by Application
11.3.6.3. Market Revenue and Volume Forecast, by Administrator
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Type
11.3.7.2. Market Revenue and Volume Forecast, by Application
11.3.7.3. Market Revenue and Volume Forecast, by Administrator
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Type
11.4.2. Market Revenue and Volume Forecast, by Application
11.4.3. Market Revenue and Volume Forecast, by Administrator
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Type
11.4.4.2. Market Revenue and Volume Forecast, by Application
11.4.4.3. Market Revenue and Volume Forecast, by Administrator
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Type
11.4.5.2. Market Revenue and Volume Forecast, by Application
11.4.5.3. Market Revenue and Volume Forecast, by Administrator
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Type
11.4.6.2. Market Revenue and Volume Forecast, by Application
11.4.6.3. Market Revenue and Volume Forecast, by Administrator
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Type
11.4.7.2. Market Revenue and Volume Forecast, by Application
11.4.7.3. Market Revenue and Volume Forecast, by Administrator
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Type
11.5.2. Market Revenue and Volume Forecast, by Application
11.5.3. Market Revenue and Volume Forecast, by Administrator
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Type
11.5.4.2. Market Revenue and Volume Forecast, by Application
11.5.4.3. Market Revenue and Volume Forecast, by Administrator
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Type
11.5.5.2. Market Revenue and Volume Forecast, by Application
11.5.5.3. Market Revenue and Volume Forecast, by Administrator
12.1. GlaxoSmithKline plc
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Agenus
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Merck KGaA
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. InvivoGen
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. CSL Limited
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Dynavax Technologies
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Croda International PLC
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. OZ Biosciences
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. SEPPIC
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. SPI Pharma
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
